These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975 [TBL] [Abstract][Full Text] [Related]
3. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Cuevas BD; Winter-Vann AM; Johnson NL; Johnson GL Oncogene; 2006 Aug; 25(36):4998-5010. PubMed ID: 16568086 [TBL] [Abstract][Full Text] [Related]
4. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700 [TBL] [Abstract][Full Text] [Related]
5. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Vasiljeva O; Papazoglou A; Krüger A; Brodoefel H; Korovin M; Deussing J; Augustin N; Nielsen BS; Almholt K; Bogyo M; Peters C; Reinheckel T Cancer Res; 2006 May; 66(10):5242-50. PubMed ID: 16707449 [TBL] [Abstract][Full Text] [Related]
6. Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. Sevenich L; Werner F; Gajda M; Schurigt U; Sieber C; Müller S; Follo M; Peters C; Reinheckel T Oncogene; 2011 Jan; 30(1):54-64. PubMed ID: 20818432 [TBL] [Abstract][Full Text] [Related]
7. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice. Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086 [TBL] [Abstract][Full Text] [Related]
8. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Szabova L; Chrysovergis K; Yamada SS; Holmbeck K Oncogene; 2008 May; 27(23):3274-81. PubMed ID: 18071307 [TBL] [Abstract][Full Text] [Related]
9. Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice. Zhang H; Kuang SQ; Liao L; Zhou S; Xu J Cancer Res; 2004 Oct; 64(19):7169-77. PubMed ID: 15466215 [TBL] [Abstract][Full Text] [Related]
10. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643 [TBL] [Abstract][Full Text] [Related]
11. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Zhang H; Stephens LC; Kumar R Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771 [TBL] [Abstract][Full Text] [Related]
13. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639 [TBL] [Abstract][Full Text] [Related]
14. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Wu Y; Cui K; Miyoshi K; Hennighausen L; Green JE; Setser J; LeRoith D; Yakar S Cancer Res; 2003 Aug; 63(15):4384-8. PubMed ID: 12907608 [TBL] [Abstract][Full Text] [Related]
15. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Almholt K; Lund LR; Rygaard J; Nielsen BS; Danø K; Rømer J; Johnsen M Int J Cancer; 2005 Feb; 113(4):525-32. PubMed ID: 15472905 [TBL] [Abstract][Full Text] [Related]
16. Human endothelial cells expressing polyoma middle T induce tumors. Primo L; Roca C; Ferrandi C; Lanfrancone L; Bussolino F Oncogene; 2000 Jul; 19(32):3632-41. PubMed ID: 10951569 [TBL] [Abstract][Full Text] [Related]
17. PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas. Trimble MS; Xin JH; Guy CT; Muller WJ; Hassell JA Oncogene; 1993 Nov; 8(11):3037-42. PubMed ID: 7692372 [TBL] [Abstract][Full Text] [Related]
18. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246 [TBL] [Abstract][Full Text] [Related]
19. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Taverna D; Crowley D; Connolly M; Bronson RT; Hynes RO Cancer Res; 2005 Nov; 65(22):10324-9. PubMed ID: 16288021 [TBL] [Abstract][Full Text] [Related]
20. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]